Open Access Published since January 1, 2023

Oncologie

ISSN: 1765-2839

Editors-in-chief: Jean Philippe Metges, Daniel Serin

Submit manuscript

About this journal

Oncologie is aimed to the publication of high quality original research articles, review papers, case report, etc. with an active interest in vivo or vitro study of cancer biology. Study relating to the pathology, diagnosis, and advanced treatment of all types of cancers, as well as research from any of the disciplines related to this field of interest.

The journal is owned by Tech Science Press. La Société Française de Chirurgie Oncologique (SFCO), France, l’Association Francophone pour les Soins Oncologiques de Support (AFSOS), France, la Fédération Française des Oncologues Médicaux (FFOM), France, and the Malaysian Association for Cancer Research (MACR), Malaysia are affiliated with the journal Oncologie.

Oncologie is an open access journal. It has French and English publications, currently publishes English-language articles mainly. The publication frequency is bimonthly.

Aims & Scope

Oncologie, an international peer-reviewed journal with a group of the global experts who are leaders in oncology in the editorial board, aims to publish high-quality original research articles, review papers, case reports, etc. with an active interest in vivo or in vitro study of cancer biology. Oncologie focuses studies relating pathology, diagnosis, and advanced treatment of cancer and research from all disciplines related to this field of interest. More specifically, we are targeting the entire fields of cancer biology, including but not limited to the discovery of any new factors related to cancer initiation, progression, and systemic treatment. Other critical biological insights are considerable for sure.

Research Topics may include Cytology, Pathology, Genetics, Gynecology, Hematology, Immunology and Immunotherapy, Chemotherapy, Radiotherapy, Palliative Support, Pediatric　Oncology, Solid Tumors, Modern Statistics, Meta-analysis, and Clinical Trial Design, Surgery, Nursing, Psycho-Oncology

Oncologie is targeted at medical and health workers engaged in cancer prevention, treatment and research, teachers and students from medical colleges and universities, and personnel in other related disciplines.

History

Former publication of Oncologie
(2004-2017): https://link.springer.com/journal/10269/volumes-and-issues
(2018-2019): https://onco.revuesonline.com/component/issues
(2019-2022): https://www.techscience.com/journal/oncologie

Abstracting and Indexing

Oncologie is covered by the following services:

Dimensions
EBSCO Discovery Service
Google Scholar
J-Gate
JournalTOCs
KESLI-NDSL (Korean National Discovery for Science Leaders)
MyScienceWork
Naver Academic
Naviga (Softweco)
Primo Central (ExLibris)
ReadCube
SCImago (SJR)
SCOPUS
Semantic Scholar
Summon (ProQuest)
TDNet
Web of Science - Science Citation Index Expanded
WorldCat (OCLC)
X-MOL
Yewno Discover

Supplementary Materials

Topics

External Links

Online submission of manuscripts

Volume 25 Issue 1

January 2023

Publicly Available March 16, 2023

Frontmatter

Page range: i-ii

Download PDF

Review Article

Open Access February 14, 2023

Differential expression and functions of miRNAs in bladder cancer

Hao Huang, Xiaowu Pi, Chenqi Xin, Chen Gong, Feng Guo, Yang Wang, Ying Xiong

Page range: 1-15

More Download PDF

Abstract

Bladder cancer (BC), a urologic disease, commonly occurs globally and is very invasive. Patients with invasive BC have low 5-year survival rate. Hence, the mechanisms underlying BC development and progression should be elucidated. MicroRNAs (miRNAs), as common noncoding RNAs, are receiving increasing attention because of their biological functions. The irregular expression patterns of miRNAs are linked to BC occurrence; therefore, determining the functions of miRNAs in abnormally expressed BC tissues might enable to elucidate the pathogenetic mechanism of BC and offer new markers for the prognosis, diagnosis, and therapy of BC. Here, we consolidate the primary roles of miRNAs with atypical expression in BC development as well as their association with BC pathological grades and chemotherapy resistance development in patients with BC.

Research Articles

Open Access February 20, 2023

Pan-cancer analysis, providing a reliable basis for IDO2 as a prognostic biomarker and target for immunotherapy

Bangqian Mo, Xiashuang Zhao, Yongfeng Wang, Xianglai Jiang, Deming Liu, Hui Cai

Page range: 17-35

More Download PDF

Abstract

Objectives Indoleamine 2,3-dioxygenase 2 (IDO2) is a homologous protein of the classical immune negative regulator Indoleamine 2,3-dioxygenase 1 (IDO1) that is indispensable in the metabolism of tryptophan and is closely related to the pathogenesis and progression of tumors. Nevertheless, the mechanism of IDO2 in malignant tumors is not fully understood warranting further research. Methods Data related to IDO2 in pan-cancer was obtained from The Cancer Genome Atlas (TCGA) database. Differences in IDO2 expression between pan-cancerous and corresponding normal tissues were analyzed, and survival rates were analyzed using Kaplan–Meier. The correlation between IDO2 expression and tumor-infiltrating immune cells (TIICs), tumor mutational load (TMB), microsatellite instability (MSI), mismatch repair (MMR), immune checkpoints (ICP) and DNA methyltransferase (DNMT) was investigated by Spearman correlation analysis. Functional enrichment analysis of IDO2 was performed to explore its biological and molecular roles in tumors. Results Our comprehensive pan-cancer analysis showed that IDO2 expression was significantly altered in most malignancies and correlated with poor prognosis. The expression of IDO2 was strongly associated with the progression of several tumors and excessive infiltration of immune cells in the tumor microenvironment (TME). The expression of IDO2 significantly correlated with TMB, MSI, MMR and ICP in different tumors. More importantly, functional enrichment analysis showed that IDO2 acts primarily through the regulation of antitumor immunological processes. RT-PCR validated IDO2 expression in multiple cancer cell lines, consistent with the bioinformatic analysis results. Conclusions IDO2 is closely related to tumor genesis and immunity, and can be used as an adjunct for the diagnosis and prognosis assessment of many tumors.

Open Access January 27, 2023

Knockdown of pyruvate kinase M2 suppresses bladder cancer progression

Guang-Cheng Luo, Ran Xu, Xi Zhang, Lin Xu, Xiao-Kun Zhao, Xin-Jun Wang

Page range: 37-50

More Download PDF

Abstract

Objectives Bladder cancer (BCa) is one of the most frequently diagnosed cancers of the urinary tract and has a high mortality. The M2 splice isoform of pyruvate kinase (PKM2) is a key regulator of the Warburg effect in cancer cells. This study aimed to evaluate metabolic alterations and biological behaviours after knocking down PKM2. Methods In this study, 36 pairs of BCa tissues and adjacent normal tissues were collected to analyse the expression level of PKM2 and to explore the relationship between PKM2 level and tumour and patient status. After PKM2 knockdown in T24 cells, cell survival, migration, invasion, glucose uptake, lactate production, and apoptosis were detected. The tumour-forming ability of PKM2-reducing T24 cells was examined in vivo . Results The results showed that PKM2 expression correlates with BCa stage and grade. PKM2 knockdown decreases glucose consumption and lactate production and suppresses cell proliferation, migration, and invasion while increasing reactive oxygen species levels and apoptosis in T24 BCa cells in vitro . In nude mouse models, PKM2 knockdown reduced xenograft and orthotopic tumour size. Moreover, PKM2 knockdown decreased vimentin and fibronectin expression and increased E-cadherin expression. Analysis of high-throughput sequencing data revealed that PKM2 may also be associated with biological processes and diseases. Conclusions Overall, these results indicate that PKM2 may be a therapeutic target for BCa patients.

Open Access February 3, 2023

Development and validation of a nomogram for predicting survival in patients with pancreatic ductal adenocarcinoma after radical pancreatoduodenectomy

Yanwei Wang, Chenghao Cui, Qiang Yu, Mingtai Li, Yurong Liang

Page range: 51-59

More Download PDF

Abstract

Objectives Hypercoagulation and malnutrition are the characteristic pathophysiological changes associated with pancreatic ductal adenocarcinoma (PDAC), which are intimately related to cancer progression and prognosis. We aimed to integrate related indicators to build a nomogram model to predict the overall survival (OS) of PDAC patients underwent radical pancreatoduodenectomy (PD). Methods Clinicopathological and survival data of 138 patients were retrospectively analyzed according to inclusion and exclusion criteria. A nomogram was built based on the multivariate Cox regression analysis. The receiver operating characteristic curve (ROC) and calibration curves were performed based on the bootstrap method to evaluate the predictive performance of the nomogram. Decision curve analysis (DCA) was performed to assess the clinical usefulness of the nomogram. Results High-grade tumor (Hazard ratio [HR]: 3.70; 95% confidence interval [CI]: 1.51–3.82; p<0.001), vessel carcinoma embolus (HR: 2.69; 95% CI: 1.30–5.31, p=0.007), N2 (HR: 2.90; 95% CI: 1.47–7.37; p=0.004), anemia (HR: 1.98; 95% CI: 1.01–2.70; p=0.047), PLR>244.8 (HR: 2.13; 95% CI: 1.05–3.45; p=0.033), FBG>3.50 g/L (HR: 2.10; 95% CI: 1.04–3.09, p=0.008), and DRR>1.1 (HR: 2.69; 95% CI: 1.56–4.27; p<0.001) served as independent risk factors for poor OS of patients with PDAC underwent radical PD and were implemented to construct a nomogram. The area under curve (AUCs) for the first, second, and third years were 0.713, 0.777, and 0.845, respectively. Besides, calibration curves fitted well to the ideal line. DCA shows that the nomogram has greater net benefit than the existing TNM staging system, suggesting that this model is a more practical clinical tool for predicting the prognosis of PDAC patients. Conclusions The nomogram we established based on the characteristic pathophysiological alterations of PDAC for predicting OS in patients who underwent radical pancreatoduodenectomy presented considerable predictive power. It may facilitate prognostic risk stratification and optimize therapeutic decision-making.

Open Access February 22, 2023

SET domain containing protein 8 (SET8) promotes tumour progression and indicates poor prognosis in patients with laryngeal squamous cell carcinoma

Li-Li Lan, Sheng-Hui Liu, Zhi-Tao Fan, Xue-Xia Wang, Jing-Tian Wang, Ke-Xin Wang, Rui-Li Zhao

Page range: 61-69

More Download PDF

Abstract

Objectives SET Domain Containing Protein 8 (SET8), a member of the SET domain containing methyltransferase family involved in several biological processes and SET8 expression levels, reportedly affects the outcomes of patients with breast cancer, renal cancer, prostate carcinoma, and oesophageal squamous cell carcinoma. However, there have been no relevant studies on the biofunction and use of SET8 expression in the prediction of laryngeal squamous cell carcinoma (LSCC) outcomes. Methods In our study, SET8 expression levels were detected using immunohistochemical staining, western blotting, and quantitative real-time RT-PCR (qRT-PCR) with semi-quantitative analysis for laryngeal cancer outcomes. Additionally, we assessed the influence of SET8 on the behaviour of laryngeal cancer cells in vitro , using cell counting kit-8, clone formation, wound healing, and Transwell invasion assays. We subsequently performed qRT-PCR and western blotting for an in-depth study of SET8. Results Our study showed marked upregulation of SET8 in tumour tissues and laryngeal cancer cell lines. High SET8 expression predicts poor prognosis in patients with LSCC, and its expression can be used as an independent predictor of LSCC outcome. Subsequent functional analyses indicated that SET8 knockdown exerted an inhibitory effect on proliferation, migration, and invasiveness in vitro. Conclusions SET8 may be associated with epithelial-mesenchymal transition. Our results demonstrate that higher SET8 expression is an unfavourable prognostic predictor and exerts tumour-promoting effects in LSCC.

Open Access February 8, 2023

Hypoxia-inducible factor 1α (HIF-1α)-activated Gli1 induces invasion and EMT by H3K4 methylation in glioma cells

Yihai Lin, Zhangyi Wu

Page range: 71-79

More Download PDF

Abstract

Objectives Gliomas are highly aggressive neuroepithelial-layer malignancies. Hypoxia-inducible factor 1α (HIF-1α) was revealed to be upregulated in gliomas under hypoxia. Nevertheless, its role in glioma cells remains elusive. We attempted to clarify the molecular mechanism of HIF-1 underlying glioma. Methods Cellular models were established to mimic the characteristics of hypoxia. RT‒qPCR was used to detect HIF-1α and Gli1 levels in glioma cells with or without hypoxic treatment. Transwell assays were used to measure the invasive ability of U87 and U251 cells. Western blotting was used to evaluate epithelial-mesenchymal transition (EMT)-associated protein abundance and H3K4 methylation (H3K4me)-associated protein abundance in U87 and U251 cells. ChIP assessed the association of HIF-1α or H3K4me with the Gli1 promoter in glioma cells. Results HIF-1α and Gli1 were upregulated in glioma cells relative to normal human astrocytes (NHAs). HIF-1α and Gli1 were also upregulated in hypoxia-treated glioma cells relative to untreated glioma cells. Both HIF-1α and Gli1 silencing suppressed glioma invasion and EMT under hypoxia. HIF-1α upregulated Gli1 transcriptionally via MLL1-mediated H3K4me. H3K4me mutation silencing was further demonstrated to suppress glioma cell invasion and EMT under hypoxia. Conclusions Both HIF-1α and Gli1 are upregulated in glioma cells and function as oncogenes in glioma cells. HIF-1α transcriptionally activates Gli1 via MLL1-mediated H3K4 methylation in glioma cells, providing ideas for seeking new therapeutic directions for glioma.

Open Access February 10, 2023

The inhibitory effects of lobaplatin, or in combination with gemcitabine on triple-negative breast cancer cells in vitro and in vivo

Chengyan Jiang, Ye Zhang, Xiaoyu Xu, Shanshan Su, Huafeng Pan, Aiqin Jiang

Page range: 81-91

More Download PDF

Abstract

Objectives To study the therapeutic effects of lobaplatin in combination with conventional chemotherapy drugs on triple-negative breast cancer (TNBC) cells. Methods We used the CCK-8 assay, flow cytometry, western blotting, and immunofluorescence staining methods to detect the effects of lobaplatin or in combination with gemcitabine on the survival, apoptosis, and cell cycle progression of TNBC cells. A cell-derived xenograft mouse model was used to verify the antitumor effects of lobaplatin alone or in combination with gemcitabine. Results Lobaplatin significantly inhibited MDA-MB-468 cell growth in vitro , either alone or in combination with gemcitabine. Lobaplatin arrested the cell cycle at the S phase, induced nuclear cell damage, and promoted apoptosis. Also, the percentage of apoptotic cells was greatly increased when lobaplatin was combined with gemcitabine. Cleaved Caspase-3 and Poly (ADP-Ribose) Polymerase-1 (PARP-1) fragments indicated that lobaplatin promoted apoptosis through the classical pathway. Lobaplatin effectively inhibited the growth of tumors in vivo . Compared with the vehicle group (567.6 ± 126.2 mm 3 ), the tumor volume of the lobaplatin group (302.7 ± 131.6 mm 3 ) was significantly reduced (p<0.01). The combination of lobaplatin and gemcitabine (207.7 ± 83.94 mm 3 ) was a little better than lobaplatin alone in the inhibition of the transplanted tumor (p>0.05). Conclusions Lobaplatin alone or in combination with gemcitabine had significant inhibitory effects on MDA-MB-468 cells in vitro . Lobaplatin also significantly inhibited the growth of nude mice xenografts. The synergistic effect between lobaplatin and gemcitabine in vivo was minimal, perhaps due to the low dose of gemcitabine used.

Case Report

Open Access February 7, 2023

Epstein–Barr virus positive gastric adenocarcinoma with systemic EBV reactivation in a patient with persistently active systemic lupus erythematosus

Rada Miskovic, Danijela Miljanovic, Maja Dimic Cumic, Ivana Lazarevic, Ana Banko

Page range: 93-97

More Download PDF

Abstract

Objectives Epstein–Barr virus (EBV) has been associated with several types of cancers, most often with nasopharyngeal carcinomas and hematological malignancies. It is also suggested that EBV has significant role in the pathogenesis of different types of autoimmune diseases including systemic lupus erythematosus (SEL). The exact mechanisms behind these processes are not elucidated. Case presentation We present a case of a 52-years old female patients with moderately active SLE presenting with severe fatigue, purpuric lesions, alopecia, polyarthritis, mucosal ulcerations, and progressive thrombocytopenia over a period of 10 months. During the work-up, the patient was evaluated for several viral infections. Serology testing showed elevation of anti-EBV, anti-CMV and anti-HSV1/2 IgM antibodies with the presence of IgG antibodies against all mentioned viruses except HSV2. Corticosteroid therapy was escalated, and azathioprine was introduced. Due to the persistence of significant thrombocytopenia and monoclonal IgG sternal puncture was performed. Morphological and immunohistochemical analysis of bone marrow specimen presented infiltration with metastatic deposits of adenocarcinoma and monoclonal plasmacytosis. Esophagogastroduodenoscopy showed multiple prepyloric erosions of gastric mucosa, which were biopsied. Pathohistological analysis demonstrated infiltration of gastric mucosa with diffuse type adenocarcinoma. Further PCR testing of biopsied gastric adenocarcinoma revealed the presence of EBV DNA in carcinoma tissue. The patient was sent to the oncologist for further evaluation. Conclusions Assessment of SLE patients with persistently active disease should include the analysis of the herpesvirus infection status. Reactivations of EBV may be considered as possible trigger for lupus flares and the factor for increased risk of developing malignancies.

Ahead of Print / Just Accepted

Ahead of Print / Just Accepted

Volume 25 (2023)

Issue 1

No ranking information is available for this journal.

Submit

Submission
You can easily submit your manuscript online.
Simply go to http://mc.manuscriptcentral.com/oncologie and you will be guided through the whole peer-reviewing and publishing process.

Your benefits of publishing with us

Open Access publication
Research freely available for all to read and download
Authors retain copyright – articles published under the Creative Commons Attribution (CC-BY-4.0) License
Rapid publication times
Free publication of color figures
Accepted papers will be published online first as DOI-citable, forward-linked articles for quickest possible visibility for the scientific community
Every article easily discoverable because of Search Engine Optimization (SEO) and comprehensive abstracting and indexing services
Professional sales and marketing activities

Submission process

Submission of your paper via our submission management tool following the Instructions for Authors
The article processing fees for publishing a research article is € 1.000
Single-blind peer review process
A decision on your paper is aspired within approx. 6 weeks
Accepted articles are published online approx. 4 weeks after acceptance

Please note

Before submitting your article please have a look at our Publication Ethics Statement and our License to Publish.
If you have any general questions please visit our FAQ page for journal authors.

We are looking forward to receiving your manuscript soon!

Editorial

Editors-in-Chief

Jean-Philippe Metges
Institut de Cancérologie et d'Hématologie, CHRU de Brest, France
Digestive cancer; Targeted therapies and immunotherapy; Clinical management

Daniel Serin
Institut Sainte-Catherine, Avignon, France
Breast cancer; Fibrocystic breast disease; Clinical oncology

Associate Editors

Jean-Yves Blay
Centre Léon Bérard, Unicancer and Université Claude Bernard Lyon 1, Lyon, France
Sarcoma; Gastrointestinal stromal tumors; Breast cancer

Mario Campone
Institut de Cancérologie de l'Ouest, Site René Gauducheau, Site Hospitalier Nord, Saint-Herblain, France
Breast cancer; Development of new drug; Translational research

Nadine Houédé
Institut de Cancérologie du Gard - CHU Caremeau; Institut de Recherche en Cancérologie de Montpellier &Université de Montpellier, France
Prostate cancer; Bladder cancer; Renal cell carcinoma

Kun Huang
Tongji School of Pharmacy, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
Liver cancer; Renal carcinoma; Drug discovery

Nicolas Isambert
Centre Hospitalier Universitaire de Poitiers, France
Cancer biology; Cancer immunology; Tumor microenvironment

Tristan Montier
Université de Bretagne Occidentale (University of Western Brittany), Brest, France
Cell and molecular biology; Gene delivery and gene therapy; Ovarian cancer

Haili Qian
State Key Laboratory of Molecular Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
Molecular oncology; Cancer biology; Immunotherapy; Tumor metastasis

Xavier Troussard
Laboratoire d'hématologie biologique, CHU de Caen Normandie, Caen, France
Leukemia; Multiple myeloma; Clinical trials

Hong Ping Xia
School of Basic Medical Sciences, Nanjing Medical University, Nanjing, China
Hepatocellular carcinoma; Oncogene; Targeted therapeutic strategy

Editorial Board

Xavier Artignan
Department of Radiation Oncology, CHP St Grégoire, St Grégoire, France
Radiotherapy; Prostate cancer

Majid Asadi-Samani
Shahrekord University of Medical Sciences, Shahrekord, Iran
Biology; Medicinal plants; Pharmacognosy; Phytomedicine; Immunology; Cancer

Hossein Banazadeh Baghi
Immunology Research Center & Infectious and Tropical Diseases Research Center, Department of Microbiology, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran
Viruses and human cancer; Viral vaccines; Viral epidemiology

Giammauro Berardi
Department of General and Hepatobiliary Surgery, Liver Transplantation Service, San Camillo Forlanini Hospital, Rome, Italy
Surgical oncology; Hepatobiliary and pancreatic surgery; Liver cancer; Liver transplantation

Fulvio Borella
Obstetrics and Gynecology 1U, S. Anna Hospital, Turin, Italy
Gynecological cancer; Breast cancer; Prognostic/predictive factors; Cancer biology

Giuseppe Broggi
Department of Medical, Surgical Sciences and Advanced Technologies "G.F. Ingrassia", Anatomic Pathology, University of Catania, Catania, Italy
Histopathology; Surgical pathology; Dermatopathology

Hong Lei Chen
Department of Pathology, Medical School of Wuhan University, Wuhan, China
Tumor immunity and immunotherapy resistance mechanism; Autophagy, energy metabolism and carcinogenesis; Pathological diagnosis of neoplasm

Delia Cannizzaro
Department of Neurosurgery, Humanitas Clinical and Research Center-IRCCS, Milan, Italy and Department of Biomedical Sciences, Humanitas University, Milan, Italy
Neurosurgery

Francesco Cicone
Department of Experimental and Clinical Medicine, and Neuroscience Research Centre, PET/RM Unit, "Magna Graecia" University of Catanzaro, Nuclear Medicine Unit, University Hospital "Mater Domini", Catanzaro, Italy
PET/CT cancer diagnostics; Nuclear medicine therapy; Brain tumor imaging

Roberto Colasanti
Department of Neurosurgery, Padua University Hospital, Ancona, Italy
Neurosurgery; Neuro-oncology (Gliomas, Metastatic brain tumors, Pineal tumors, etc.); Brain mapping; Skull base (Meningiomas, Schwannomas, etc.); Spine tumors

Jianxun Ding
Key Laboratory of Polymer Ecomaterials, Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, Changchun, China
Bioactive agents for tumor microenvironment regulation; Bioactive polymers for controlled delivery of antineoplastic agents; Bioactive polymers as adjuvants for cancer immunotherapy

Maya Dymova
Laboratory of Biotechnology, Institute of Chemical Biology and Fundamental Medicine, Siberian Branch of the Russian Academy of Sciences (ICBFM SB RAS), Novosibirsk, Russia
Mycobacterium tuberculosis; Molecular genetics; Molecular oncology

Yujiang Fang
Department of Microbiology & Immunology, Des Moines University, Des Moines, USA
Pathology of oncology; Cancer immunotherapy; Cancer radiosensitizer

Valéria Pereira Ferrer
Department of Cell and Molecular Biology, Fluminense Federal University, Rio de Janeiro, Brazil
Prostate cancer and glioblastoma;Extracellular matrix; Angiogenese; New therapies and biomarkers; Molecular biology; Cell biology; Biochemistry; Oncology; Toxinology

Jean-Sébastien Frénel
Département d’Oncologie Médicale, Institut de Cancérologie de l’Ouest, Saint-Herblain, France
Breast cancer; Gynecological cancer; Circulating biomarker

Nicola Fusco
Biobank for Translational and Digital Medicine Unit, IRCCS European Institute of Oncology (IEO); Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy
Breast pathology; Predictive pathology; Digital pathology; Translational research

Zhaohui Gong
Biochemistry and Molecular Biology, Ningbo University School of Medicine, Ningbo, China
Targeted therapy; Immunotherapy; Precision medicine

Frank Griesinger
Department of Haematology & Oncology, University Department Internal Medicine-Oncology, Pius-Hospital, University Medicine Oldenburg, Germany
Thoracic Oncology; Non-Small Cell Lung Cancer

Gu He
Medicinal Chemistry, West China Hospital, Sichuan University, Chengdu, China
Cancer biology; Chemical biology; Computation chemistry

Xiaoyun He
Department of Ultrasound Imaging, Xiangya Hospital, Central South University, Changsha, China
Molecular targeted therapy for metabolic diseases; Vascular endothelial tumors

Yi Hu
State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Science, Beijing, China
Nanomedicines; Mitochondria; Macrophage

Guichun Huang
Medical Oncology Department of Jinling Hospital, Medical School of Nanjing University, Nanjing, China
Tumor angiogenesis; Tumor microenvironment; Cancer immunotherapy

Haroon Khan
Department of Pharmacy, Faculty of Chemical & Life Sciences, Abdul Wali Khan University, Mardan, Pakistan
Metabolic diseases; Pharmacology; Antioxidant activity

Ivana Lazarevic
Institute of Microbiology and Immunology, Faculty of Medicine, University of Belgrade, Belgrade, Serbia
Viral genetic variability; Hepatitis viruses; Antiviral resistance

Anne Lesur
Institut de Cancérologie de Lorraine, Nancy, France
Clinical oncology; Breast cancer; Endocrine therapy

Xiangpan Li
Cancer Center, Renmin Hospital of Wuhan University, Wuhan, China
Clinical research: Follow-up; Materials collection and analysis; Research design; Clinical epidemiology: Medical research method; Statistic analysis; Lab skills: Animal model of lung cancer; cell culture; HE staining; PCR etc.

Yuchen Liu
Key Laboratory of Medical Reprogramming Technology, First Affiliated Hospital of Shenzhen University, Shenzhen, China
Cancer Biology; DNA&RNA editing; Synthetic biology

François Lucia
Radiation Oncology Department, University Hospital of Brest, France
Gynecological Oncology

Xiaobin Lv
Cancer Center Lab, the Third Affiliated Hospital of Nanchang University, Nanchang, China
Post-translational modification; Non-coding RNA; Chemotherapy resistance

Fabio Medas
General Surgery and Consultant at Department of General and Endocrine Surgery at University Hospital of Cagliari, Cagliari, Italy
Cancer Surgery; Parathyroid carcinoma; Hernias

Jialin Meng
Department of Urology, the First Affiliated Hospital of Anhui Medical University; Institute of Urology and Anhui Province Key Laboratory of Genitourinary Diseases, Anhui Medical University, Hefei, Anhui, China
Cancer biology; Immunotherapy; Urologic disease; Biomarkers; Bioinformatics

Laurent Mineur
Institut Sainte-Catherine, Avignon, France
Gastric adenocarcinomas; Colorectal cancer; Liver tumors

Cem Önal
Department of Radiation Oncology, Faculty of Medicine, Adana Dr. Turgut Noyan Research and Treatment Center, Baskent University, Adana, Turkey
Prostate cancer; Breast cancer; Gynecological malignancies; Radiotherapy/radiosurgery; Helical tomotherapy

Armando Orlandi
Comprehensive Cancer Center, UOC di Oncologia Medica, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy
Breast cancer

Chunlin Ou
Department of Pathology, Xiangya Hospital Central South University, Changsha, China
Exosomal long non-coding RNAs; Oxidative stress; Colorectal cancer

Carlos Eduardo Paiva
Division of Breast & Gynecology, Department of Clinical Oncology, Barretos Cancer Hospital, Barretos-SP, Brazil
Palliative and supportive care; Breast cancer; Quality of life

Stefano Rausei
University of Milan, Department of Surgery, ASST Valle Olona (Varese), Varese, Italy
Surgical oncology; Gastric cancer; Colon cancer; Minimally invasive
surgery; Emergency surgery

Kandasamy Saravanakumar
Department of Medical Biotechnology, College of Biomedical Sciences, Kangwon National University, Chuncheon, South Korea
Cellular antioxidant properties; Antibacterial activity; Paraconiothyrium brasiliense

Gianluca Scalia
Department of Head and Neck Surgery, Neurosurgery Unit, Garibaldi Hospital, Catania, Italy
Gliomas; Meningiomas; Spine tumors

Mohsen Sheykhhasan
Research Center for Molecular Medicine, Hamadan University of Medical Sciences, Hamadan, Iran
Stem Cell; CAR T cell therapy; Exosomes

Hardeep Singh Tuli
Department of Biotechnology, Maharishi Markandeshwar University, Haryana, India
Cancer biology; Cell signaling; Gene expression

Johnson Stanslas
Pharmacotherapeutics Unit, Department of Medicine, Faculty of Medicine and Health Sciences, Universiti Putra Malaysia, Serdang, Malaysia
Clinical and experimental pharmacology; Drug discovery; Translational therapeutics; Cancer research and neuroscience

Farzad Taghizadeh-Hesary
Department of Radiation Oncology, Iran University of Medical Sciences, Tehran, Iran
Radiation oncology; Clinical radiotherapy; Radiation biology; Combined modality therapy; Medical oncology; Chemotherapy; Targeted therapies; Cancer biology

Dilek Telci
Department of Genetics and Bioengineering, Yeditepe University, Istanbul, Turkey
Cell signaling in cancer; Cell adhesion; Migration and metastasis; Animal models in cancer

Giuseppe E. Umana
Department of Neurosurgery, Cannizzaro Hospital, Trauma Center, Gamma Knife Center, Catania, Italy
Neuro-oncology; Stereotactic radiosurgery; Skull base; gliomas; Meningiomas; Schwannomas; Craniovertebral junctions tumors; Spine tumors; Peripheral nerve sheath tumors

Dimitrios-Efthymios Vlachos
First Department of Obstetrics and Gynecology University of Athens, Greece
Gynecological Oncology

Feng Wang
Department of Clinical Laboratory Center, Affiliated Hospital of Nantong University, Nantong, China
Tumor pathogenesis; Cancer molecular diagnosis; Non-coding RNA

Dongkui Xu
Department of VIP, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
Colorectal cancer; Gastric cancer; Surgery, including minimally invasive surgery

Kexin Xu
Department of Molecular Medicine, University of Texas Health Science Center at San Antonio, San Antonio, USA
Epigenomics; Functional genomics; Genome editing

Tao Xu
School of Pharmacy, Anhui Medical University, Hefei, China
The mechanism of liver inflammation; Pathogenesis of alcoholic liver disease; Hospital humanities

Shun Fa Yang
Institute of Medicine, Chung Shan Medical University, Taiwan, China
Biomarkers; Environmental toxicology; Cell signaling

Paul Zarogoulidis
Pulmonary Department, "General Clinic Euromedica" Private Hospital, Thessaloniki, Greece
Lung cancer diagnosis and treatment; Drug design development and therapy

Yingchun Zeng
School of Medicine, Zhejiang University City College, Hangzhou, China
Clinical psychology; Nursing science; Rehabilitation medicine

Wenwen Zhang
Department of Oncology, Nanjing First Hospital, Nanjing Medical University, Nanjing, China
Breast cancer; Metastasis; Biomarkers

(Deutsch)

Type: Journal
Languages: English, French
Publisher: De Gruyter
First published: January 1, 2023
Publication Frequency: 6 Issues per Year